These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 9535034)

  • 1. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
    Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
    Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of poor marrow graft function with allogeneic CD34+ cells immunoselected from G-CSF-mobilized peripheral blood progenitor cells of the marrow donor.
    Arseniev L; Tischler HJ; Battmer K; Südmeier I; Casper J; Link H
    Bone Marrow Transplant; 1994 Nov; 14(5):791-7. PubMed ID: 7534162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.
    Lickliter JD; McGlave PB; DeFor TE; Miller JS; Ramsay NK; Verfaillie CM; Burns LJ; Wagner JE; Eastlund T; Dusenbery K; Weisdorf DJ
    Bone Marrow Transplant; 2000 Oct; 26(7):723-8. PubMed ID: 11042652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
    Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
    Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.
    Keever-Taylor CA; Klein JP; Eastwood D; Bredeson C; Margolis DA; Burns WH; Vesole DH
    Bone Marrow Transplant; 2001 Apr; 27(8):791-800. PubMed ID: 11477435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ; Fishleder A; Andresen SW; Lichtin AE; Koo A; Yanssens T; Burwell R; Baucco P; Green R
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.